it’s clear why management don’t respond to shareholders.they...

it’s clear why management don’t respond to shareholders.

they don’t neeed us anymore - they got all their shares approved by us before the NASDAQ and are sitting happy, waiting for results. they are likely thinking that results will drive the share price - not shareholder sentiment. But the last time, it was sentiment which drove the share price to 70 cents. Hotcopper was really different back then - a positive place.

now the company is fundamentally better and about to release phase 2b results - management likely think this will be enough to show the market and turn around the share price. I hope it is. But unfortunately if shareholder sentiment isn’t there (which it isn’t as confidence is at all time lows), the news event will prob turn into another pump and dump.

we are written off by the US market as just another unicorn pie in the sky Penny dreadful punt. If we weren’t, we certainly wouldn’t be capped at $27M or so before a major news event.

this is prob because there is another drug approved by the FDA to treat moderate sleep apnoea in November last year - Zepbound (terzepatide) developed by major pharma Eli Lilly. They have asked the FDA to expand the approval to severe cases- not only moderate. A decision is due by the end of year.

very unfortunate times for ASX shareholders